Pharmacology & ToxicologyMolecular OncologyPeer-reviewed
PARP inhibition enhances exemestane efficacy in triple-negative breast cancer
Nur Aininie Yusoh, Liping Su, Suet Lin Chia…·Martin R. Gill
This study identifies Exemestane as a synergistic partner for Olaparib in triple-negative breast cancer, enhancing efficacy through DNA damage and apoptosis.
4 citations